Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim in Children With Bone Marrow Failure
NCT04478227Phase 1Completed
- Start
- Aug 2020
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of romiplostim in bone marrow failure, aplastic anemia, myelodysplastic syndrome (MDS) and 1 more (2 arms). Primary endpoints: Occurrence of treatment-related adverse events and Improvement in hematopoiesis at 24 weeks. Started Aug 2020; status: completed.
02
Drugs
romiplostim
03
Conditions
bone marrow failureaplastic anemiamyelodysplastic syndrome (MDS)Thrombocytopenia
Beyond the preview
Go deeper on NCT04478227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04478227.